Mélanges de poésie.

Poème de Tobie (1). — Mag. Alexandri Laus sapientiae divinae {40). — Pièces de vers composées par Jo. Prevost (89), Fr, Caulier (90), Lud. Hurillon (91, 93), J. Mentel (94), N. Leon. Bursarius (95), J. Fr. Mondolot. (96), Fr. Boutard (99), Am. du Mas (106), Car. Thiery (112), Ben. Thibaud (113), Fr. de Clermont Thoury (139), Pet, Neveletus. Doschius (169), Car. Fr. Thiery (184), Seb. Tripier (276), Franc. Linant (323), Jos. Rosset (351), Rob. Wallery (363), Ren. Pr. Tassin (371), Jo. Henr. Wentsel (373). — Extr. du ms. 553 du Vatican (104). — Lettre des religieux de Tiron à Jean Casimir, roi de Pologne (178). — Épitaphes et inscriptions modernes, plusieurs composées par Mabillon. — Deux vieilles épitaphes de l'église de: Lagny (262). Inscription antique de Vicence (311). — Distiques de l'abbé Serlon (355). Épitaphe. de Ratherius (356). — Qq. pièces en français et en italien.

Geological explorations in Central Borneo (1893-94) : Borneo expedition. english rev. ed. with an appendix on fossil radiolaria of Central-Borneo ([Reprod.]) / by Dr. G. A. F. Molengraaff,... ; by Dr. G. J. Hinde

Comprend : Description of fossil radiolaria from the rocks of Central Borneo, obtained by prof. Dr. G. A. F. Molengraaff in the dutch exploring expedition of 1893-94

Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: Ten-year Follow-up of a Randomized Phase III Trial (SAKK 10/94)

Purpose/Objective(s): To analyze the long-term outcome of treatment with concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer compared with hyperfractionated radiotherapy alone.Materials/Methods: From July 1994 to July 2000 a total of 224 patients with squamous cell carcinoma of the head and neck were randomized to either hyperfractionated radiotherapy (median dose 74.4 Gy; 1.2 Gy twice daily) or the same radiotherapy combined with two cycles of concomitant cisplatin (20mg/m2 for 5 consecutive days of weeks 1 and 5). The primary endpoint was time to any treatment failure; secondary endpoints were locoregional failure, metastatic failure, overall survival, and late toxicity assessed according to RTOG criteria. The trial was registered at the National Institutes of Health (www.clinicaltrials.gov; identifier number: NCT00002654).Results: Median follow-up was 9.5 years (range, 0.1 - 15.4 years). Median time to any treatment failure was not significantly different between treatment arms (p = 0.19). Locoregional control (p\0.05), distant metastasis-free survival (p = 0.02) and cancer specific survival (p = 0.03) were significantly improved in the combined treatment arm, with no difference in late toxicity between treatment arms. However, overall survival was not significantly different (p = 0.19). Conclusions: After long-term follow-up combined treatment with cisplatin and hyperfractionated, radiotherapy maintained an improved locoregional control, distant metastasis-free survival, and cancer specific survival as compared to hyperfractionated radiotherapy alone with no difference in late toxicity.Author Disclosure: P. Ghadjar, None; M. Simcock, None; G. Studer, None; A.S. Allal, None; M. Ozsahin, None; J. Bernier, None; M. To¨ pfer, None; F. Zimmermann, None; C. Glanzmann, None; D.M. Aebersold, None.

Characteristics and outcome of 27 elbow periprosthetic joint infections: results from a 14-year cohort study of 358 elbow prostheses.

Elbow arthroplasty is increasingly performed in patients with rheumatic and post-traumatic arthritis. Data on elbow periprosthetic joint infection (PJI) are limited. We investigated the characteristics and outcome of elbow PJI in a 14-year cohort of total elbow arthroplasties in a single centre. Elbow prosthesis, which were implanted between 1994 and 2007 at Schulthess Clinic in Zurich, were retrospectively screened for infection. PJI was defined as periprosthetic purulence, the presence of sinus tract or microbial growth. A Kaplan-Meier survival method and Cox proportional hazard analysis were performed. Of 358 elbow prostheses, PJI was identified in 27 (7.5%). The median patient age (range) was 61 (39-82) years; 63% were females. Seventeen patients (63%) had a rheumatic disorder and ten (37%) had osteoarthritis. Debridement and implant retention was performed in 78%, followed by exchange or removal of the prosthesis (15%) or no surgery (7%).The relapse-free survival (95% CI) was 79% (63-95%) after 1 year and 65% (45-85%) after 2 years. The outcome after 2 years was significantly better when patients were treated according to the algorithm compared to patients who were not (100% vs. 33%, p <0.05). In 21 patients treated with debridement and retention, the cure rate was also higher when the algorithm was followed (100% vs. 11%, p <0.05). The findings of the present study suggest that the treatment algorithm developed for hip and knee PJI can be applied to elbow PJI. With proper patient selection and antimicrobial therapy, debridement and retention of the elbow prosthesis is associated with good treatment outcome.